Analytical Data
-
Gene name
CD82
- Application
-
Alternative Names
CD82；KAI1；SAR2；ST6；CD82 antigen
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P27701
-
Expression Region
1-267aa
-
AA Sequence
MGSACIKVTKYFLFLFNLIFFILGAVILGFGVWILADKSSFISVLQTSSS SLRMGAYVFIGVGAVTMLMGFLGCIGAVNEVRCLLGLYFAFLLLILIAQV TAGALFYFNMGKLKQEMGGIVTELIRDYNSSREDSLQDAWDYVQAQVKCC GWVSFYNWTDNAELMNRPEVTYPCSCEVKGEEDNSLSVRKGFCEAPGNRT QSGNHPEDWPVYQEGCMEKVQAWLQENLGIILGVGVGVAIVELLGMVLSI CLCRHVHSEDYSKVPKY
-
Molecular Weight
55 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD82, also known as the KI-1 antigen, is a member of the tetraspanin family of proteins and plays a crucial role in cell adhesion, migration, and immune response regulation. It is widely expressed in various immune cells, including T cells, B cells, and antigen-presenting cells, suggesting its significance in modulating immune functions. Research indicates that CD82 is involved in tumor progression and metastasis, serving both as a suppressor and promoter in different cancer types, which makes it an intriguing target for therapeutic interventions. Additionally, the expression levels of CD82 have been correlated with clinical outcomes in several cancers, further highlighting its potential as a biomarker for cancer prognosis. Recent studies have explored the use of CD82 recombinant proteins in immunotherapy, aiming to leverage its capacity to enhance immune responses against tumors. By better understanding the biological functions and mechanisms of CD82, researchers hope to develop novel strategies that could improve cancer treatment outcomes and provide insights for the development of immunotherapeutic agents. The advancement of recombinant technology has facilitated the production of CD82 proteins, allowing for in-depth investigations into its structural characteristics and functional capabilities. Consequently, the ongoing research on CD82 recombinant proteins not only enhances our understanding of immune modulation but also paves the way for potential clinical applications in cancer therapy and beyond.
